Market Overview

JMP Securities Downgrades Enanta Pharma To Market Perform


Analysts at JMP Securities downgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from “market outperform” to “market perform” and removed the price target of $50.

Enanta Pharma shares have surged 145.97% over the past 52 weeks, while the S&P 500 index has gained 21.67% in the same period.

Enanta Pharma's shares gained 1.23% to close at $42.75 on Thursday.

Latest Ratings for ENTA

Dec 2018BerenbergInitiates Coverage OnBuy
Aug 2018OppenheimerDowngradesOutperformPerform
Jun 2018Roth CapitalInitiates Coverage OnBuy

View More Analyst Ratings for ENTA
View the Latest Analyst Ratings

Posted-In: JMP SecuritiesDowngrades Analyst Ratings


Related Articles (ENTA)

View Comments and Join the Discussion!

Latest Ratings

DPLOMorgan StanleyMaintains8.0
QLYSSummit Insights GroupDowngrades0.0
BTXRaymond JamesMaintains5.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

B Riley Initiates Bazaarvoice At Buy

BMO Capital Upgrades Southern Copper To Outperform